<-- Back to proposed bills
Covid-19 Update
05 September 2022
Type
Written Ministerial Statement
Department
Department of Health and Social Care
At a Glance
Issue Summary
The statement provides an update on the ongoing Covid-19 vaccination programme in the UK, focusing on the autumn booster programme and new vaccine authorisations.
Action Requested
The government is deploying authorised bivalent vaccines and Nuvaxovid for eligible individuals as part of the autumn booster programme. The House is updated on the liabilities Her Majesty’s Government has taken to secure further vaccine supply.
Key Facts
- Over 126 million doses have been provided, including 45.2 million first doses, 42.6 million second doses and 33.5 million third primary and booster doses in the UK.
- The JCVI advises that for the 2022 autumn booster programme, certain groups should be offered a Covid-19 booster vaccine to optimise protection against severe Covid-19 over winter 2022/23.
- Moderna’s BA1/wild-type bivalent vaccine was authorised on 12 August 2022 and Pfizer’s BA1/wild type bivalent vaccine on 3 September 2022 by the MHRA.
- Nuvaxovid, the Novavax Covid-19 vaccine, may be used off-label as a booster dose for persons aged 18 years and above when no alternative clinically suitable UK-approved Covid-19 vaccine is available.
▸
Assessment & feedback
Summary accuracy